Literature DB >> 29782562

First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC.

Biagio Ricciuti1, Rita Chiari1.   

Abstract

Entities:  

Year:  2018        PMID： 29782562      PMCID： PMC5943230          DOI： 10.21037/tlcr.2018.03.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  16 in total

1.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Authors:  James Chih-Hsin Yang; Yi-Long Wu; Martin Schuler; Martin Sebastian; Sanjay Popat; Nobuyuki Yamamoto; Caicun Zhou; Cheng-Ping Hu; Kenneth O'Byrne; Jifeng Feng; Shun Lu; Yunchao Huang; Sarayut L Geater; Kye Young Lee; Chun-Ming Tsai; Vera Gorbunova; Vera Hirsh; Jaafar Bennouna; Sergey Orlov; Tony Mok; Michael Boyer; Wu-Chou Su; Ki Hyeong Lee; Terufumi Kato; Dan Massey; Mehdi Shahidi; Victoria Zazulina; Lecia V Sequist
Journal:  Lancet Oncol       Date:  2015-01-12       Impact factor: 41.316

2.  Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  S Novello; F Barlesi; R Califano; T Cufer; S Ekman; M Giaj Levra; K Kerr; S Popat; M Reck; S Senan; G V Simo; J Vansteenkiste; S Peters
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

3.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

4.  Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Authors:  James Chih-Hsin Yang; Myung-Ju Ahn; Dong-Wan Kim; Suresh S Ramalingam; Lecia V Sequist; Wu-Chou Su; Sang-We Kim; Joo-Hang Kim; David Planchard; Enriqueta Felip; Fiona Blackhall; Daniel Haggstrom; Kiyotaka Yoh; Silvia Novello; Kathryn Gold; Tomonori Hirashima; Chia-Chi Lin; Helen Mann; Mireille Cantarini; Serban Ghiorghiu; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2017-02-21       Impact factor: 44.544

5.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

Review 6.  Mechanisms of resistance to EGFR-targeted drugs: lung cancer.

Authors:  Floriana Morgillo; Carminia Maria Della Corte; Morena Fasano; Fortunato Ciardiello
Journal:  ESMO Open       Date:  2016-05-11

7.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245

8.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Authors:  Glenwood Goss; Chun-Ming Tsai; Frances A Shepherd; Lyudmila Bazhenova; Jong Seok Lee; Gee-Chen Chang; Lucio Crino; Miyako Satouchi; Quincy Chu; Toyoaki Hida; Ji-Youn Han; Oscar Juan; Frank Dunphy; Makoto Nishio; Jin-Hyoung Kang; Margarita Majem; Helen Mann; Mireille Cantarini; Serban Ghiorghiu; Tetsuya Mitsudomi
Journal:  Lancet Oncol       Date:  2016-10-14       Impact factor: 41.316

9.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Authors:  Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397

Review 10.  Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer.

Authors:  Xiaomin Liu; Ping Wang; Caiyan Zhang; Zhongliang Ma
Journal:  Oncotarget       Date:  2017-07-25
View more
  2 in total

1.  EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing.

Authors:  Lucio Lettig; Nora Sahnane; Francesco Pepe; Roberta Cerutti; Chiara Albeni; Francesca Franzi; Giovanni Veronesi; Francesca Ogliari; Alessia Pastore; Alessandro Tuzi; Graziella Pinotti; Antonella Bovio; Claudio Verusio; Monica Giordano; Giancarlo Troncone; Fausto Sessa; Umberto Malapelle; Daniela Furlan
Journal:  Transl Lung Cancer Res       Date:  2019-10

2.  Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma.

Authors:  Zhiqiang Gao; Weimin Wang; Aiqin Gu; Jianhong Lu; Aimi Huang; Liwen Xiong; Baohui Han; Liyan Jiang; Chunlei Shi
Journal:  Transl Lung Cancer Res       Date:  2020-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.